STOCKHOLM, May 15, 2019 /PRNewswire/ -- Moberg Pharma
AB's ("Company") Annual General Meeting took place on Wednesday, May 15th, 2019 in the Company´s
premises in Bromma, Sweden.
Adoption of the income statements and the balance sheets
The Annual General Meeting (the "Meeting") approved the income
statements and the balance sheets for the fiscal year 2018.
The Meeting resolved, in accordance with the proposal of the
Board of Directors, that no dividend should be paid for the fiscal
year 2018.
The Meeting discharged the Board members and the Chief Executive
Officer from liability for the fiscal year 2018.
Board of Directors
In accordance with the proposal of the Nomination Committee, the
Meeting resolved that the Board of Directors shall consist of four
(4) persons and no deputies.
The Meeting resolved re-election of Mattias Klintemar and
Andrew B. Hochman as Board members
of the Board of Directors for a period until the next Annual
General Meeting. Thomas Eklund has,
after three years as Chairman of the Board and four years as Board
member, chosen to resign. Geert
Cauwenbergh, Sara Brandt and
Anna Malm Bernsten have chosen to
resign in order to enable a composition of the Board of Directors
that is better adapted to the Company's new situation and focus. In
accordance with the proposal of the Nomination Committee, the
Meeting resolved election of Peter
Wolpert as new Board member and executive Chairman of the
Board of Directors, and Fredrik Granström as new Board
member.
The Meeting resolved, in accordance with the proposal of the
Nomination Committee, that an aggregate fee of SEK 870,000 shall be paid to the Board members,
of which SEK 360,000 to the Chairman
of the Board of Directors and SEK
170,000 for all other Board members elected by the Annual
General Meeting. In order to compensate for the additional work
that Peter Wolpert will perform in
the Company in the capacity of executive Chairman of the Board, the
Meeting resolved, in accordance with the proposal of the Nomination
Committee, on a fee of SEK 61,000 per
month to Peter Wolpert for the part
of the work that lies outside the role of Chairman of the
Board.
Fees to the Auditors, for a period until the end of the next
Annual General Meeting, are to be paid as per approved invoice.
Nomination Committee
The Meeting resolved, in accordance with the proposal of the
Nomination Committee, that the Company shall have a Nomination
Committee consisting of four (4) members. The Nomination Committee
shall comprise one representative of each of the three largest
shareholders or owner groups in the Company in terms of votes as
per March 31, 2019, besides the
Chairman of the Board of Directors.
Principles for remuneration
The Meeting resolved to approve the Board of Director's proposal
for principles of remuneration to senior executives in Moberg
Pharma.
Transfer of shares to cover costs related to previous incentive
programs
The Meeting also resolved to approve the Board of Director's
proposal to transfer shares to cover costs related to incentive
programs implemented previous years.
New CEO
Immediately following the General Meeting and in accordance with
the proposal dated on April 8th, 2019
(http://www.mobergpharma.com/press-releases/2019-04-08/proposed-management-changes-moberg-pharma),
the Board of Directors resolved to elect Anna Ljung as the new Chief Executive Officer of
Moberg Pharma AB.
About this information
Moberg Pharma discloses the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments
Trading Act. The information was submitted for publication at
5:30 pm (CET) on May 15th, 2019.
CONTACT:
For additional information, please contact:
Peter Wolpert, Chairman of the
Board, telephone: +1-908-432-22-03 (US), +46-70-735-71-35
(Sweden), e-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CEO, telephone:
+46-707-66-60-30, e-mail: anna.ljung@mobergpharma.se
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/moberg-pharma/r/bulletin-from-moberg-pharma-s-agm-2019,c2814717
The following files are available for download:
https://mb.cision.com/Main/1662/2814717/1045891.pdf
|
Bulletin from Moberg
Pharma’s AGM 2019
|
View original
content:http://www.prnewswire.com/news-releases/bulletin-from-moberg-pharmas-agm-2019-300850868.html
SOURCE Moberg Pharma